<DOC>
	<DOCNO>NCT00774917</DOCNO>
	<brief_summary>This prospective single centre Study design assess OCT effect NUMEN cobalt-chromium balloon-expandable stent induce neointimal hyperplasia de novo native coronary lesion patient Stable Angina Pectoris ACS ( except STEMI ) . A total 60 consecutive patient enrol study . Patients de novo native coronary artery lesion &gt; 10mm &lt; 24mm length &gt; 2.50mm &lt; 3.50mm diameter QCA estimate meet eligibility criterion enrol undergone stent implantation . After stent deployment OCT imaging perform within treat segment . Patients follow 30 day , 6 month 12 month post-procedure , patient repeat angiography OCT 6 month . It anticipate total length study 18 month : 6 month complete patient enrolment 12 month follow-up .</brief_summary>
	<brief_title>Numen Stent Assessment Using OCT Technique Single Center Study</brief_title>
	<detailed_description>OBJECTIVES The main objective study assess long term influence NUMEN cobalt-chromium balloon-expandable coronary stent neointimal hyperplasia de novo native coronary lesion patient Stable Angina Pectoris Acute Coronary Syndrom ( ACS ) - except STEMI . ENDPOINTS The primary endpoint assessment development neointimal hyperplasia OCT stented segment 6-month follow-up . Breakdown secondary endpoint : Degree endothelialization stent internal wall OCT 6 month stent implantation ; Composite Major Adverse Cardiac Events ( MACE ) define cardiac death , non-fatal myocardial infarction ( MI ) ( Q wave non-Q wave ) , emergent bypass surgery , stent thrombosis , repeat target lesion revascularization 30 day , 6 month 12 month post-procedure . Angiographic binary restenosis ( &gt; 50 % diameter stenosis ) 6 month post-procedure . Target vessel failure 6 month post-procedure . Device success define achievement final residual diameter stenosis &lt; 30 % ( Quantitative Coronary Angiography ( QCA ) ) , use assigned device . If QCA available , visual estimate diameter stenosis use . Lesion success define attainment &lt; 30 % residual stenosis ( QCA ) use percutaneous method . Procedure success define achievement final diameter stenosis &lt; 30 % ( QCA ) use percutaneous method , without occurrence death , MI , repeat revascularization target lesion hospital stay . Acute ( 24 hr post procedure ) , subacute ( 30days post procedure ) late ( &gt; 30days post procedure ) thrombosis . OVERVIEW OF THE STUDY This prospective single centre Study design assess OCT effect NUMEN cobalt-chromium balloon-expandable stent induce neointimal hyperplasia de novo native coronary lesion patient Stable Angina Pectoris ACS ( except STEMI ) . A total 60 consecutive patient enrol study . Patients de novo native coronary artery lesion &gt; 10mm &lt; 24mm length &gt; 2.50mm &lt; 3.50mm diameter QCA estimate meet eligibility criterion enrol undergone stent implantation . After stent deployment OCT imaging perform within treat segment . Patients follow 30 day , 6 month 12 month post-procedure , patient repeat angiography OCT 6 month . It anticipate total length study 18 month : 6 month complete patient enrolment 12 month follow-up .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<criteria>INCLUSION CRITERIA Patients must meet following criterion : 1 . The patient must &gt; 18 year age ; 2 . Diagnosis stable angina pectoris define Canadian Cardiovascular Society Classification ( CCS I , II , III , IV ) ACS ( except STEMI ) . 3 . Treatment de novo lesion major coronary artery patient single twovessel disease . 4 . Target vessel diameter lesion site &gt; 2.50mm &lt; 3.50mm diameter ( QCA ) ; 5 . Target lesion &gt; 10mm &lt; 24mm length ( visual estimate ) ; 6 . Target lesion stenosis &gt; 50 % &lt; 100 % ( visual estimate ) ; 7 . Acceptable candidate coronary artery bypass surgery ( CABG ) ; 8 . Patient willing comply specify followup evaluation ; 9 . Patient must provide write informed consent prior procedure use form approve local Ethics Committee . EXCLUSION CRITERIA Patients exclude follow condition apply : 1. multiple lesion vessel ; 2 . ACS STEMI ( within 48 hour ) 3. vessel size &lt; 2.50mm &gt; 3.50mm reference diameter ; 4. length lesion &gt; 24 mm ; 5. unprotected leave main coronary disease &gt; 50 % stenosis ; 6. ostial target lesion ; 7. target lesion venous graft ; 8. angiographic evidence thrombus within target lesion ; 9. calcify lesion successfully predilated ; 10 . Documented leave ventricular ejection fraction &gt; 25 % ; 11 . Impaired renal function ( creatinine &gt; 3.0 mg/dl ) time treatment ; 12 . Pretreatment device balloon angioplasty ; 13 . Prior stent within 5mm target lesion ; 14 . Recipient heart transplant ; 15 . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix ) ticlopidine ( Ticlid ) , heparin , cobalt , chromium , contrast agent ( manage medically ) 16 . Recent ( 6 month ) cerebrovascular accident intracranial hemorrage 17 . Any significant medical condition investigator 's opinion may interfere patient 's optimal participation study ; 18 . Currently participate investigational drug another medical device study ; 19 . In investigator 's opinion , lesion suitable stenting . 20 . Life expectancy â‰¤ 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>numen</keyword>
	<keyword>hyperplasia</keyword>
</DOC>